Review experiences of global ARV shortages Clarisse Morris, MA February 2006.

Slides:

Advertisements

Similar presentations

Resource requirements for reaching the treatment goals under PEPFAR XV International AIDS Conference Bangkok July 15, 2004 Owen Smith, Abt Associates Inc.

Advertisements

2 nd line and recent ARVs prices and access issues Carmen Pérez Casas Access Campaign MSF May 2006.

A brief overview of ART services at QECH, Malawi Kudzala Aub. MMEDsc. Student Sr. Lead ART Clinician/ HIV Medicine Registrar.

Providing Quality Medicines for People Living with and Affected by HIV and AIDS Supply Chain Management System Project The Partnership for Supply Chain.

Group III: Demand Forecasting

1 CHAI ARV Procurement Database Clinton Foundation HIV/AIDS Initiative November 7, 2005.

Harmonization of donor reporting requirements for antiretrovirals and related drugs Presented at the WHO meeting, Geneva ( October 2005) Oteba Olowo.

THE INTERNATIONAL DRUG PURCHASE FACILITY-UNITAID Michel D. Kazatchkine, Ministère des Affaires Etrangères, France.

Brazil: from universal ARV access to universal HCV treatment? Juliana Vallini Friday, 23rd, July, 2010.

World Health Organization

Scaling Up Access and Rational Drug Use Anthony D. So, MD, MPA Program on Global Health and Technology Access Sanford School of Public Policy Duke University.

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

BUY Recommendation: Gilead Sciences (GILD). Company Overview Gilead Sciences, Inc. is a research-based biopharmaceutical company found in 1987 that discovers,

XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.

Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.

The International Response to HIV/AIDS Josh Busby Princeton University Center for Globalization.

Access to ARVs : good news bad news David Henry WHO Collaborating Centre for Rational Use of Drugs The University of Newcastle NSW.

Update by IDA Foundation Leontien Ruttenberg MSc MBA.

Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.

UN Prequalification: UNICEF Perspective 5 th UN Prequalification stakeholders meeting 11th February 2009.

Ashley Morris Erica Shnayder Adam Percy Nana Sang-Bender.

A very short introduction to patents & access to medicines.

1 |1 | Prequalification Programme – Stakeholders Meeting Geneva, February 2010 Access to Assured-Quality Praziquantel for the Control of Human Schistosomiasis.

The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.

1 Situation of Current ARV Treatment in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Funding Universal Access through a “Global Health Charge” on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew.

Impacts of TRIPS on access to care The post-2005 issues Benjamin CORIAT University Paris 13 and ANRS ANRS – MoH Brazil Satellite Meeting Mexico, August.

Demand for and Supply of Greebes PRICE $ per Greebe QUANTITY DEMANDED (millions of Greebes) QUANTITY SUPPLIED (millions of Greebes) $

Funding Universal Access through a “Global Health Charge” on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew.

Nov 2004Access to Paediatric ARV formulations ENSURING SECURE and RELIABLE SUPPLY and DISTRIBUTION SYSTEMS in DEVELOPING COUNTRIES, in the CONTEXT OF HIV/AIDS.

Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.

Downloaded from Current Status of ART Opportunities & Challenges Kibrebeal Melaku,MD Associate Professor.

Experience with common basket for ARV procurement Tanzania Emma Lekashingo Msuya.

What do we mean with ‘ there is no access to Paediatric ARV Formulations ’ ?

1 Introduction to the Clinton Foundation HIV/AIDS Initiative 12 July 2007 Africa Recruit.

WHO/Roll Back Malaria – 3 May Forecast of ACT needs based on current and expected changes in antimalarial treatment policies Procurement, Quality.

From 3by5 to Universal Access to HIV/AIDS Treatment: AMDS Technical Briefing Seminar for Consultants on Procurement and Supply Management for HIV, TB and.

Affordability of HIV/AIDS treatment in developing countries: an analysis of ARV drug price determinants Luis Sagaon Teyssier; Yves Arrighi; Boniface Dongmo.

Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.

World Health Organization "3 by 5" Target Treat 3 million by 2005.

1 SUPPLY DIVISION Procurement and Supply Management Technical Assistance.

Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.

Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.

Treatment as Prevention and Treatment 2.0 Update UN Forum on AIDS, 24 June 2011 Nicole Seguy, Zhang Lan, WHO.

1 SUPPLY DIVISION Procurement and Supply Management Technical Assistance.

Thomas Eingle, R.Ph. Inpatient Pharmacy Supervisor James A. Haley Veterans Hospital, Tampa, Fl.

Pan American Health Organization 1 PAHO Technology, Healthcare and Research Project of Essential Medicine and Biologicals Linking Technical Cooperation.

Tensions between Brazil and the United States

World Health Organization "3 by 5" Target Access to HIV/AIDS Medicines The 3x5 strategy WHO/EDM Technical Briefing Seminar.

1 Scaling-up ARV therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.

TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.

WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.

1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.

3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.

Optimizing the Cost and Quality of HIV / AIDS Care and Treatment Anil Soni, Clinton HIV / AIDS Initiative 19 th Board Meeting, Geneva 6 May 2009.

UNITAID actions and main achievements Investing in the quality of medicines XVII International AIDS Conference Satellite Forum WHO – Essential Medicines.

Moving towards a Patent Pool? XVII International AIDS Conference Satellite Forum, MSF, KEI, OXFAM (Mexico, 5 August 2008) Jorge Bermudez Executive-Secretary,

Characterizing the South Africa ART Market

Procurement and Supply Management Policies

IDA Solutions Clarisse Morris, MA January 2006

Expanding ARV treatment in developing countries: Issues and Prospects

Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.

World Health Organization

Overview of the AMDS Products

The HIV Epidemic among People who Inject Drugs

Forecasting – HIV/AIDS commodities Key challenges and lessons learned

Consolidated Technical Support Plan for AIDS

Demand Forecasts for for HIV/AIDS ARV formulations

Product selection issues

WHO Global HIV/AIDS Staff Meeting

Presentation transcript:

Review experiences of global ARV shortages Clarisse Morris, MA February 2006

Slide 2 Issues in global ARV shortages 1.Increase in the number of patients on treatment. 2.Change in the recommended treatment guidelines. 3.Increase in the number of patients on 2nd line regimens.

Slide 3 1.Increase in the number of patients on treatment GFATM aims to finance treatment for 1.8 million people by PEPFAR aims to have 2 million people on treatment by This scale up puts pressure on the production capacity of: –ARV manufacturers; –ARV raw material manufacturers.

Slide 4 Recent ARV shortages Zerit (Stavudine-d4T) by Bristol Myers Squibb; All GlaxoSmithKline ARVs containing Zidovudine (ZDV); Epivir (Lamivudine-3TC) by GSK; Stockrin (Efavirenz-EFV) by Merck.

Slide 5 Recent ARV shortages (cont’d) Generics (temporarily) removed from WHO prequalification list

Slide 6 2.Change in recommended treatment guidelines Last WHO ARV treatment guidelines date from Revision is scheduled for Possibly 3 drugs will be added to the 1st line regimen. An increased demand for these drugs could fuel shortages.

Slide 7 3.Increase in the number of patients on 2nd line regimens Needed for people worldwide within the next 2 years. Costs are more than 10x the 1st line treatment price. Clinton HIV/AIDS Initiative’s 2006 aim: lowering prices of 2nd line drugs. Lower prices mean more people can be treated. Increased demand could cause shortages.

Slide 8 References Demand for two AIDS treatments could soon exceed supply by Paul Davies, Wall Street Journal, Medicine procurement of ARVs and other essentiel medicines in the U.S. Global AIDS programs by Sharonann Lynch, Health Gap, November Clinton HIV/AIDS Foundation Press Release: New agreements to lower prices of HIV/AIDS rapid tests and 2nd line drugs, January agreements-to-lower-prices-of-hiv-aids-rapid-tests-and-second-line-drugs.htm Update on China and India and Access to Medicines by Cheri Grace, DFID, November